THE ROLE OF GENETIC TESTING FOR INHERITED PROSTATE CANCER RISK

 The consensus will define the role of genetic testing in inherited prostate cancer risk assessment. The recommendations will serve men and their families with all stages of prostate cancer and other genetically-related cancers. A major journal paper is being prepared to serve as a guide to patients, providers and researchers in the field. Other professional organizations will be invited to review the final recommendations and consider endorsing the consensus conclusions.

 Since the issue of genetic testing involves inherited risk for prostate cancer and encompasses risks for other cancers affecting males and females, each host organization had a clear stake in addressing the proposed critical consensus topics. 

  Program Co-Chairs:   

Leonard G. Gomella, MD, Chair Dept. of Urology, Senior Director Clinical Affairs,   SKCC 

Karen Knudsen, PhD, Director SKCC, Chair Cancer Biology 

Veda Giri, MD, Director, Cancer Risk Assessment and Clinical Cancer Genetics, 

Associate Professor, Department of Medical Oncology  and Cancer Biology 

Steering Committee: 

Wm. Kevin Kelly DO (SKCC)  Chair Stephen Peiper MD(SKCC), Gordon Schwartz MD (FBPH) Co-Chairs, Daniel Petrylak MD (Yale), Eric Klein MD (Cleveland Clinic), Dan Lin MD (U Washington), Howard Sandler MD (Cedars Sinai), Gerry Andriole MD (Wash U), Elias Obeid MD (FCCC), Jeannie Hoffman-Censits MD, Bobby Den MD, Adam Dicker MD, Mark Hurwitz MD, Costas Lallas MD, Peter McCue MD, Ron Myers PhD, Mark Shahin MD, Edouard Trabulsi MD (All SKCC).     

  Administrative Support: 

Ms. Denise Tropea ,Jefferson Urology, Sidney Kimmel Cancer Center  and 

Mrs. Colleen Daley, Executive Director, Foundation for Breast and Prostate Health. 

  Participants   

The meeting included over 60 stakeholders in the area of genetic testing for prostate cancer inherited risk. Consensus members and faculty included urologists, medical oncologists, radiation oncologists, pathologists, gynecologists, primary care providers, community urologists, genetic counselors, social workers, bioethicists’, basic science researchers, and patient advocates. Experts in related inherited cancers that can impact prostate cancer in areas such as breast, ovarian and GI cancers participated. Many recognized thought leaders in the area of genetic testing attended the consensus as faculty providing state of the art lectures.   

The professional participants represented a “who’s who” of major medical centers from across the US. A partial listing of centers and programs represented includes the Sidney Kimmel Cancer Center at Jefferson, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Fox Chase Cancer Center, Sidney Kimmel Cancer Center at Hopkins, University of Colorado, Ohio State, the Cleveland Clinic, the University of Pennsylvania, Brigham & Women's Hospital/Harvard Medical School, UC San Francisco, Duke University, University of Utah, Dana Farber Cancer Center, University of Michigan, Vanderbilt, Yale, UT Southwest, University of Oklahoma, University of Washington, MD Anderson Cancer Center, UC San Diego, the National Cancer Institute, Weill Cornell Medicine-NY Presbyterian Hospital, Cedars-Sinai Medical Center, Tulane, Brown, Columbia, Northwestern, the American Cancer Society, Prostate Conditions Education Council, The Prostate Cancer Foundation, and the University of Chicago. International participants included representatives from the University of Toronto, Oxford University England and Erasmus University, the Netherlands.   

Our keynote speaker addressed “A Patient’s Perspective on Familial Prostate Cancer Risk Assessment”. Mr. Robin Cole, Retired Pittsburgh Steeler and founder of the OBEDIAH Foundation discussed his personal challenges and those faced by his father and his brothers due to familial prostate cancer.  

HOST ORGANIZATIONS